Stocks To Buy Now Blog

Stocks on Radar

ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) Well Positioned to Take Advantage of Oil-Driven Inflation and the Continued High Gold Prices

Disseminated on behalf of ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) and may include paid advertising.

  • ESGold Corp., a development-stage company committed to the acquisition, exploration, and development of high-quality mineral properties worldwide, is optimistic about historically high gold prices
  • With the ongoing global political issues, there has been oil-driven inflation and a general lack of faith in traditional stores of wealth, which experts note are long-term drivers of gold prices
  • ESGold has positioned itself to take advantage of this growth, being fully funded to execute, and is on track to kicking off production at its flagship Montauban Gold-Silver Project in Quebec
  • Gordon Robb, ESGold’s CEO, has noted that 2026 will be a major year for the company, with important milestones being achieved, and with ongoing market factors in their favor

ESGold (CSE: ESAU) (OTCQB: ESAUF), a development-stage company committed to acquiring, exploring, and developing high-quality mineral properties worldwide, remains optimistic about gold prices in 2026 and is positioning itself to take advantage of it. This comes amid growing oil-driven inflation and debt factors which continues to highlight gold as a safety hedge, both for the short-term and long-term (https://ibn.fm/BGLjF).

As of May 21, 2026, the price of gold was trading at $4,504 an ounce, up from $3,312 a year ago. According to JPMorgan, it is projected that by year-end, this price will likely hit close to $6,000 per troy ounce, a key signal pointing to the potential gold has for growth and its viability as an important hedge investment vehicle (https://ibn.fm/waijw).

The ongoing global issue as well as the high price of crude oil are key to shaping this outcome as time progresses. Higher oil prices have increased inflation risks, all while increasing chances of higher-for-longer interest rates. Regardless, ESGold believes there is still value in gold as a hedge against this inflation and looks to capitalize on its anticipated uptake.

“Given the current high negative correlation to oil, dollar, and yields, these – especially oil – will set the tone for gold in the upcoming sessions,” noted Ole Hansen, head of commodity strategy at Saxo Bank (https://ibn.fm/BGLjF).

Back in the 1970s, high inflation, paired with weak economic growth, led to massive gains in gold. Between 1976 and 1080, the price of a troy ounce grew from $125 to $859. The pattern was further replicated in the 2020s, when there was a global inflationary spike, with gold serving as a crucial defensive asset, which led to its price rising. Experts point out that the pattern might repeat itself this year as well, with the ongoing global political climate and the oil-induced inflation. As a result, ESGold is positioning itself to capitalize on the spike in demand and the accompanying surge in gold prices.

Thus far, the company has positioned itself for growth and set itself up for success. It is fully funded to execute and is on track to kick off production at its flagship Montauban Gold-Silver Project in Quebec. Earlier this month, it expanded its Montauban footprint with a 2,448-hectare strategic claim and bolstered its senior leadership, with Jason Tong as its new Chief Financial Officer (“CFO”). Gordon Robb, the company’s CEO, has reiterated that 2026 will be a big year 2026 will be for ESGold, and the steps taken so far, the milestones achieved, and the current state of the world, it is safe to say that the company is on track to have its best year yet.

For company information, visit the company’s website at www.ESGold.com.

NOTE TO INVESTORS: The latest news and updates relating to ESAUF are available in the company’s newsroom at https://ibn.fm/ESAUF

Regentis Biomaterials Ltd. (NYSE American: RGNT) Is ‘One to Watch’

  • GelrinC(R) is positioned as a potential first-in-class, off-the-shelf solution for knee cartilage repair in the U.S., offering a single-step procedure that simplifies treatment and integrates into standard surgical workflows.
  • Clinical data show ~100% greater pain improvement versus microfracture, with durable outcomes and MRI-confirmed regeneration of near-native cartilage.
  • A single ~10-minute procedure with ~2-week recovery and lower costs versus cell-based therapies supports strong adoption across surgeons, payers, and patients.
  • The product targets an estimated ~$3 billion U.S. market with ~470,000 annual cases and no comparable ready-to-use competitor.
  • Advancing through a pivotal Phase III trial with CE Mark approval in Europe, the company is approaching key catalysts including commercialization and FDA submission.

Regentis Biomaterials (NYSE American: RGNT) is taking aim at a $3 billion U.S. market with what could be the first true off-the-shelf solution for knee cartilage repair—no cells, no delays, no complexity. Its GelrinC(R) platform delivers faster recovery, stronger outcomes, and lower costs vs. outdated procedures, with clinical data showing ~100% greater pain improvement vs. microfracture. Already CE Mark approved in Europe and advancing through a pivotal U.S. Phase III trial, Regentis is stacked with near-term catalysts that could redefine orthopedic care—and unlock massive upside.

Company Overview

Regentis is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. With an initial focus on knee injuries and other orthopedic treatments, Regentis’ Gelrin(TM) platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. Regentis’ lead product GelrinC(R) is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing the surrounding cells to regenerate durable and healthy cartilage in a controlled and synchronous process with sustained results. GelrinC(R) aims to address an estimated $3 billion annual U.S. market of approximately 470,000 cases of knee cartilage repair, where no off-the-shelf treatment is available. It has CE Mark approval for commercialization in Europe and has completed more than 50% enrollment in its pivotal Phase III study for U.S. FDA approval. Several upcoming value-driving catalysts include completion of the U.S. pivotal trial, commercialization in Europe, and submission for FDA approval in the U.S.

Investment Highlights

Positioned as a First-in-Class Off-the-Shelf Solution for Knee Cartilage Repair in the U.S.

GelrinC(R) is built to disrupt a broken standard of care. A true single-step, off-the-shelf implant, it eliminates cell harvesting, lab delays, and multi-stage surgeries. While legacy treatments are either ineffective or overly complex, GelrinC(R) delivers a fast, ~10-minute procedure that fits seamlessly into existing workflows. This is a category-defining product with the potential to displace both microfracture and expensive cell-based therapies.

Compelling Clinical Efficacy That Outperforms Legacy Treatments

GelrinC(R) isn’t just simpler—it’s clinically superior. Data shows ~100% greater improvement in pain scores vs. microfracture at two years, with durable, multi-year outcomes and no adverse events to date. MRI results confirm near-complete cartilage regeneration, the gold standard in the field. This is the rare combination investors look for: clear, measurable superiority with lasting results.

Stronger Economics That Accelerate Adoption

GelrinC(R) aligns with how healthcare actually works: faster, cheaper, and easier. A single minimally invasive procedure, ~2-week recovery (vs. ~6 weeks), and significantly lower costs than $40K+ cell therapies create a powerful value proposition. The result: high-margin scalability with strong incentives for surgeons, payers, and patients alike.

Large, Underpenetrated Market with Clear Catalysts Ahead

Targeting a ~$3B U.S. market with ~470K annual cases, GelrinC(R) is entering a space with massive unmet demand and no true off-the-shelf competitor. With CE Mark approval already secured in Europe and a U.S. pivotal trial over 50% enrolled, Regentis is approaching major value inflection points—including trial completion, FDA submission, and commercialization. This is a high-upside, catalyst-rich story investors can’t ignore.

Leadership Team

Ehud Geller, PhD, MBA, Chief Executive Officer and Executive Chairman, brings extensive leadership experience in the pharmaceutical and biotechnology industries, having previously served as President and CEO of Interpharm Laboratories and as an executive vice president at Teva Group, along with leadership roles in industry organizations and public markets.

Galit Reske, PhD, Chief Medical Officer, has significant expertise in clinical development and regulatory strategy, including leading roles in global clinical operations and contributing to the FDA approval of the cartilage repair product Agili-C, which was later acquired by Smith+Nephew in a $330 million transaction.

Ori Gon, CPA, Chief Financial Officer and Chief Business Officer, has more than 15 years of financial leadership experience across public and private companies and has led multiple capital raises totaling over $150 million.

Nadya Lisovoder, MD, Director of Clinical Operations, has broad experience managing clinical studies across multiple geographies and therapeutic areas, overseeing programs from early-stage development through regulatory submission in the United States, Europe, Israel, and Australia.

For more information, visit the company’s website at https://www.regentis.co.il.

NOTE TO INVESTORS: The latest news and updates relating to RGNT are available in the company’s newsroom at https://ibn.fm/RGNT

ETHWomen and ETHToronto Return to Blockchain Futurist Conference Toronto 2026

Two of the Web3 community’s most recognized programming tracks rejoin Canada’s flagship event, bringing dedicated developer and women-focused experiences to Rebel Entertainment Complex this July

Blockchain Futurist Conference is pleased to confirm that both ETHWomen and ETHToronto will once again be featured as part of the 2026 Toronto programme, taking place July 21–22 at Rebel Entertainment Complex and Cabana Pool Bar.

Now in its fifth annual edition, ETHToronto returns on July 22 as the Web3 developer experience at Blockchain Futurist Conference. Organized by the team behind some of Canada’s longest-running crypto events since 2013, ETHToronto brings together builders, hackers, developers, and innovators from across Ethereum and the broader Web3 ecosystem. ETHToronto 2026 is proudly sponsored byAutheo. The event is free to register and open to all conference attendees, running as a dedicated programming track within the Futurist venue. Registration is available at www.ethtoronto.ca.

ETHWomen returns across both conference days, July 21–22, as a dynamic and community-driven experience dedicated to connecting, celebrating, and advancing women in the Web3 and blockchain space. Now an established fixture within Blockchain Futurist Conference, ETHWomen has grown into a global initiative that convenes hundreds of women through sessions focused on networking, collaboration, and learning. This year’s programming will also feature a breakfast sponsored by SheFi and a facilitated networking session sponsored by Women in Crypto. Free passes are available and tickets are limited, so those interested are encouraged to register early at www.ethwomen.com.

Confirmed ETHWomen 2026 speakers include Staci Warden, CEO of the Algorand Foundation; Ada Vaughan, Senior Director of DeFi Partnerships at the Stellar Development Foundation; Janet Adams, Board Member of the Artificial Superintelligence Alliance and COO of SingularityNet; Jaime Leverton, CEO of ReserveOne; and Lisa Loud, Executive Director of Secret Network. Additional speakers will be announced in the weeks ahead.

Both ETHWomen and ETHToronto are included with the purchase of a General Pass to Blockchain Futurist Conference Toronto 2026, reinforcing the conference’s commitment to providing a multi-layered, high-value experience across the full two days. Together with the AI Futurist Conference, Beginner Bootcamps, and the broader Canada Crypto Week side event programming, they reflect Futurist’s ongoing investment in building an event ecosystem rather than a single-day show.

ETHWomen will also make its return in the United States alongside the Florida edition of Blockchain Futurist Conference, with dates set for November 17–18, 2026.

Conference Tickets (includes ETHWomen & ETHToronto): futuristconference.com/toronto/ticket

ETHWomen Sponsorships: ethwomen.com/sponsorship-form

ETHToronto Registration (Free): www.ethtoronto.ca

ETHWomen Registration (Free): www.ethwomen.com

For media passes or media inquiries, please contact james@futuristconference.com

Safe Pro Group Inc. (NASDAQ: SPAI) Experiences Rapid, High Margin Revenue Increase and Launches a New Growth Team

Disseminated on behalf of SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) and may include paid advertising.

  • AI-powered security and defense solutions company Safe Pro Group recently released its financial results for the quarter ending March 31, 2026, showing a 560% quarterly revenue increase, driven by 2,400% growth in its high margin AI revenue, and a strong balance sheet.
  • In addition to finances, Safe Pro also revealed some operational highlights, such as delivering Edge processing systems to the U.S. Government, offering support for Edge processing, an expanded leadership team, and a growing interest in its solutions.
  • Safe Pro also launched a new growth team, led by Brian Mack as Chief Growth Officer and Benjamin Chitty, VP of Government Growth, which will lead its efforts to capture U.S. government contract awards through teaming agreements with Prime Contractors.

Safe Pro Group (NASDAQ: SPAI), a tech company that delivers AI-powered security and defense solutions, recently revealed its financial results for the quarter ending March 31, 2026 (https://ibn.fm/RLuo5). The highlights showed significant growth driven by the sales of its AI products.

Safe Pro Group’s quarterly revenue rose to over $1,220,129, up from the $184,8092 reported in the first quarter of 2025. This represents a 560% increase. Safe Pro AI quarterly revenue jumped over 2,400%, largely driven by new contracted sales of its AI-powered and drone-based video and image analysis systems.

Safe Pro’s quarterly consolidated gross margins were more than 68% inclusive of deprecation, validating its scalable business model. At the end of the quarter, Safe Pro supported a strong balance sheet with $14.8 million in cash and only minimal debt.

The company also covered important operational results from the quarter.

This includes Safe Pro delivering multiple Edge processing systems under a $1,000,000 government contract, as well as a contract modification that expanded this to also include providing support for these Edge processing systems.

The interest in Safe Pro’s Navigation, Observation & Detection Engine (“NODE”), and the new NODE-X miniaturized Edge processing solution, continues to grow following several live demonstrations and exercises conducted by the U.S. Army. By participating in these events, Safe Pro has the opportunity to directly engage with decision-makers in the defense industry who may be able to offer a path to product acquisition and deployment.

The company has also expanded its leadership team, and launched a new Growth Team (https://ibn.fm/AQtOI). The team is led by Brian Mack as the Chief Growth Officer and Benjamin Chitty as the VP of Government Growth. This group is leading Safe Pro’s efforts to get more U.S. government awards via teaming agreements with Prime Contractors.

Speaking about these results and the future of Safe Pro, the Chairman and CEO of Safe Pro Group, Dan Erdberg, said that “We believe Safe Pro is well positioned to capitalize on the AI era with the momentum we see building for our patented AI solutions within the U.S. Government. Supported by a strong balance sheet, expanded team of accomplished military acquisition specialists, and an enhanced portfolio of real-world proven solutions, we are excited about our future.”

About Safe Pro Group Inc.

Safe Pro Group is a mission-driven tech company that delivers advanced and AI-powered security and defense solutions to industries like law enforcement, humanitarian, homeland security, and defense. It offers drone-based services and ballistic protective gear, and the core of Safe Pro’s offering is its patented computer vision software technology that can rapidly detect small objects in drone-based videos and images, to enable more efficient and safe field operations.

For more information, visit Safe Pro Group’s website at www.SafeProGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to SPAIF are available in the company’s newsroom at https://ibn.fm/SPAIF

LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) Continues to Expand Gold Mineralization at Depth at its Swanson Gold Deposit

Disseminated on behalf of LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) and may include paid advertising.

  • Near-term gold producer LaFleur Minerals is reporting new assay results from infill diamond core drilling that bolster expectations that mineralization remains open at depth and along strike in the company’s Swanson Gold Deposit
  • The findings follow up on the mineral resource estimate completed earlier this year with the potential for additional high-grade shoots within the system and broader zones of gold mineralization
  • LaFleur’s nearly 22,400-hectare Swanson and McKenzie East gold projects are located within the prolific Abitibi Greenstone Belt of eastern Canada, within the Val-d’Or mining camp where labor and supply resources are centralized for mining operations in the region

Infill diamond-core drilling continues to yield a path to the potential expansion of resources in the Abitibi Greenstone Belt-situated Swanson Gold Deposit owned and operated by near-term gold producer LaFleur Minerals (CSE: LFLR) (OTCQB: LFLRF).

The company’s flagship property in Eastern Canada’s prolific gold mining district — one of the largest gold belts in the world — combined with the recently acquired McKenzie East Gold Project nearby, covers more than 450 exploration mining claims that are located on nearly 22,400 hectares (about 55,350 acres).

LaFleur’s May 12 news release provides an outline of significant assay results from the company’s ongoing drilling program at its Swanson Gold Deposit, highlighting findings of 2.95 g/t Au over 80.00 meters, 2.37 g/t Au over 88.05 meters, 1.29 g/t Au over 93.85 meters, and 0.86 g/t Au over 103.55 meters plus 1.14 g/t Au over 56.65 meters in four of the seven newly reported drill holes (https://ibn.fm/FcTIO).

The assays have increased confidence that continuity of mineralization exists both within and beyond LaFleur’s proposed pit shell at depth, enhancing the mineral resource estimate completed just a few months ago with the potential for high-grade shoots within the system at depth.

The drill program focused on previously untested depths where spacing between historical drill holes exceeded 50 meters, establishing higher grade sub-intervals, such as 232.00 g/t Au over 0.50 meters, 3.98 g/t Au over 9.00 meters and 7.78 g/t Au over 1.90 meters between two of the holes and leaving mineralization open at depth and along strike.

Visible gold was encountered in three of the seven recently drilled holes. 

“LaFleur has intersected some of the strongest and widest gold mineralization to date at its Swanson Gold Project, indicating the presence of broad zones of gold mineralization extending beyond the limits of the current open pit resource at the Swanson Gold Deposit and highlighting the emergence of a potentially much larger, high-growth gold system with compelling expansion potential,” LaFleur Chairman Kal Malhi stated.

Swanson is located in the Val-d’Or mining district — an established central hub for labor and other resources that support mineral exploration activities in the Abitibi. The company completed a Preliminary Economic Assessment (“PEA”) in March that anticipates a strong economic return from the project and the company’s nearby Beacon Gold Mill, which is expected to resume gold production operations during the next quarter.

LaFleur is building its profitability forecast on a base case price closer to where gold traded in January 2025 instead of current levels, meaning that the metal’s price remains far above the level LaFleur sees as the foundation for its strategy. The gold market has since achieved historic highs as it more than doubled value after January 2025, and the precious metal continues to trade at lofty levels despite recent price fluctuations that have sometimes challenged the expectations of investors (https://ibn.fm/luwBz).

For more information, visit the company’s website at LaFleurMinerals.com.

NOTE TO INVESTORS: The latest news and updates relating to LFLRF are available in the company’s newsroom at https://ibn.fm/LFLRF

Qualified Person Statement:

All scientific and technical information contained in this article has been reviewed and approved by Louis Martin, P.Geo. (OGQ), Exploration Manager and Technical Advisor of the company and considered a Qualified Person for the purposes of NI 43-101.

Oncotelic Therapeutics Inc. (OTLC) Advances CNS Drug Delivery Strategy as BBB Breakthroughs Drive New Biotech Market Opportunity

  • OTLC completed a $12.5M monetization of its N2B CNS delivery system with Lunai Bioworks, targeting Alzheimer’s and biodefense applications
  • The deal grants field-specific IP rights while preserving Oncotelic’s development in other CNS indications
  • The move aligns with the rising industry focus on blood-brain barrier (“BBB”) bypass technologies and platform-based CNS drug delivery

Oncotelic Therapeutics (OTCQB: OTLC) is advancing its position in one of biotechnology’s most persistent and commercially significant challenges: drug delivery to the central nervous system (“CNS”). As the industry increasingly recognizes the blood-brain barrier (“BBB”) as a primary constraint in neurological drug development, companies developing delivery-focused platforms are gaining increased attention across both biodefense and healthcare markets (ibn.fm/zuYfT).

According to a recent BioMedWire editorial, “CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities,” this shift is highlighted, noting that the BBB prevents the majority of therapeutics from reaching the brain and contributes to higher failure rates in CNS drug pipelines. With the increase in Alzheimer’s disease cases globally and biodefense preparedness becoming a growing priority, the article underscores that innovation is focused on bypassing biological barriers rather than solely on developing new drug compounds.

In this context, Oncotelic Therapeutics is advancing its proprietary intranasal nose-to-brain (“N2B”) delivery system, created to bypass the BBB and enable direct therapeutic access to the CNS. The platform highlights a wider industry transition toward scalable, platform-based delivery technologies capable of addressing multiple high-value indications, including neurodegenerative disease and emergency medical countermeasures.

The company recently announced the closing of an important monetization agreement with Lunai Bioworks, Inc., involving its N2B delivery system. In this agreement, Oncotelic granted worldwide rights to the N2B intellectual property within defined fields of Alzheimer’s disease and biodefense medical countermeasures. In return, the company recently received $12.5 million in Series B convertible preferred stock. Oncotelic retains development rights in additional CNS indications, including Parkinson’s disease and other therapeutic areas.

The transaction highlights a dual-track strategy: near-term value realization through targeted IP monetization, alongside long-term optionality across broader CNS applications. Management noted that the company continues to evaluate additional partnerships to monetize its portfolio further while maintaining strategic control over its core assets.

The N2B system itself represents a device-enabled intranasal delivery approach created to transport therapeutic agents directly into CNS pathways, bypassing systemic circulation constraints. This mechanism is especially relevant in both chronic neurodegenerative diseases and acute biodefense scenarios, where rapid brain delivery and targeted neurological action are vital (ibn.fm/nG4eS).

The Alzheimer’s disease market ranks as one of the biggest unmet needs in the global healthcare ecosystem, with millions of patients worldwide and continued growth expected as populations grow older. Despite significant research investment, many therapies fail in clinical development due to insufficient brain penetration, underscoring the importance of improved delivery mechanisms.

Beyond commercial healthcare, CNS delivery technologies are also gaining relevance in biodefense and national security applications. Government agencies, including BARDA and the U.S. Department of Defense, continue to prioritize medical countermeasures capable of rapid CNS intervention in response to chemical and biological threats.

As the biotechnology sector increasingly shifts toward platform-based innovation, delivery technologies such as N2B are becoming central to long-term value creation. Oncotelic Therapeutics’ continued advancement and monetization of its CNS delivery platform positions the company within this emerging segment, where solving the delivery bottleneck may prove as important as drug discovery itself.

Public-market examples such as Sangamo Therapeutics, Inc. (SGMO), CytoDyn Inc. (CYDY), Netlist, Inc. (NLST), and NorthWest Biotherapeutics, Inc. (NWBO) demonstrate continued investor appetite for platform-driven companies built around proprietary technology ecosystems, infrastructure-layer intellectual property, and long-duration scientific optionality beyond any single product candidate.

For more information, visit the company’s website at www.Oncotelic.com.

NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at ibn.fm/OTLC

Planet Ventures Inc. (CSE: PXI) (OTC: PNXPF) Strengthens Foothold in Next-Generation Space Infrastructure Technologies with Key Investment

Disseminated on behalf of Planet Ventures Inc. (CSE: PXI) (OTC: PNXPF) and may include paid advertising.

  • The importance of space exploration and commercialization has grown dramatically in recent years.
  • Planet Ventures’ recent investment in Lux Aeterna reflects a strategic effort to gain exposure to technologies tied to the next phase of the commercial space industry.
  • Lux Aeterna is a space infrastructure company building the industry’s first fully reusable satellite platform.

Space exploration is increasingly viewed not only as a scientific endeavor but also as a major economic and technological frontier capable of reshaping communications, energy systems, manufacturing and national security. Governments and private companies are investing billions into technologies that could support a long-term space economy, creating opportunities for investors seeking exposure to emerging infrastructure and advanced aerospace systems. Planet Ventures (CSE: PXI) (OTC: PNXPF) is positioning itself within that evolving landscape through a new investment in Lux Aeterna, a space infrastructure company building the industry’s first fully reusable satellite platform.

The importance of space exploration and commercialization has grown dramatically in recent years. According to the World Economic Forum and McKinsey & Company, the global space economy could reach approximately $1.8 trillion by 2035 as space-enabled technologies become increasingly integrated into communications, navigation, energy, logistics and defense systems. The report highlights how space is evolving from a niche sector into a foundational layer of global infrastructure.

Much of the early commercial space industry focused primarily on launch providers and satellite deployment. However, the market is now shifting toward technologies that support long-term operations in orbit, including robotic systems, in-space servicing, autonomous spacecraft and orbital infrastructure. Agencies such as NASA have repeatedly emphasized that sustainable space operations will require advanced technologies capable of supporting persistent activity in orbit and beyond.

This broader evolution is helping drive interest in companies developing infrastructure-oriented solutions rather than simply launch systems. The ability to service spacecraft, extend mission life, improve orbital efficiency and reduce operational costs is becoming increasingly important as more governments and businesses rely on satellites and space-based systems.

Planet Ventures’ recent investment in Lux Aeterna reflects a strategic effort to gain exposure to technologies tied to the next phase of the commercial space industry. Planet Ventures announced an investment in Lux Aeterna, stating that the company is leading a structural shift in the global space economy, which has spent decades optimizing around a disposable satellite model.

The announcement notes that Lux Aeterna’s reusable fleet of satellites is designed to close the loop on the orbital supply chain and create a persistent logistics layer between Earth and orbit. This concept is significant because most satellites today are either stranded in orbit due to a system failure, retired to a graveyard orbit, or burned up on reentry. Technologies that allow servicing, refueling or redeployment of satellites could substantially improve the efficiency and economics of orbital infrastructure.

Planet Ventures’ investment aligns with the company’s broader strategy of identifying emerging technologies capable of benefiting from long-term industry transformation. The company is focused on sectors including artificial intelligence, robotics, space technology and next-generation infrastructure systems.

The strategic importance of reusable and serviceable spacecraft technologies is also gaining recognition across the broader industry. The European Space Agency has highlighted in-orbit servicing and satellite sustainability as critical priorities for the future of commercial and governmental space operations. As the number of satellites in orbit increases, the ability to maintain and extend the usefulness of these assets may become essential to managing congestion, reducing debris and improving operational resilience.

Planet Ventures’ investment represents more than a simple portfolio addition. It reflects participation in a larger shift occurring within the commercial space sector, where value creation is increasingly moving toward enabling technologies and infrastructure solutions. Rather than focusing solely on launch providers, investors are beginning to look at companies building the systems that can support long-duration and scalable economic activity in space.

The investment may also strengthen Planet Ventures’ broader positioning within the space technology ecosystem. The company has previously highlighted exposure to orbital energy systems and space robotics through investments connected to Mantis Space and General Astronautics. Adding Lux Aeterna expands that thematic approach by introducing exposure to satellite sustainability and servicing technologies, areas expected to become increasingly important as orbital infrastructure grows more complex.

As commercial space activity continues expanding, infrastructure-oriented technologies may become some of the most strategically valuable components of the sector. Satellites, communications networks and orbital systems will require maintenance, servicing and operational support if the broader space economy is to mature sustainably. Companies developing those capabilities could therefore occupy an increasingly important role in the sector.

For Planet Ventures, the Lux Aeterna investment appears aligned with a long-term view that the next stage of space commercialization will be defined not only by reaching orbit but by building the infrastructure needed to operate there efficiently. By investing in reusable and serviceable spacecraft technologies, the company is positioning itself around what many industry observers believe could become one of the most important trends in the evolving space economy.

For more information, visit www.PlanetVenturesInc.com.

NOTE TO INVESTORS: The latest news and updates relating to PNXPF are available in the company’s newsroom at https://ibn.fm/PNXPF

Disclaimer

Investor Brand Network (“We” or “Us”) are not securities dealers or brokers, investment advisers or financial advisers, and you should not rely on the information herein as investment advice. Planet Ventures Inc. will make aggregate payments of $100,000  to us to provide marketing services for a term of 1 year. This article is informational only and is solely for use by prospective investors in determining whether to seek additional information. This does not constitute an offer to sell or a solicitation of an offer to buy any securities. Our stock profiles are intended to highlight certain companies for your further investigation; they are not stock recommendations or constitute an offer or sale of the referenced securities. The securities issued by the companies we profile should be considered high risk; if you do invest despite these warnings, you may lose your entire investment. Please do your own research before investing, including reading the companies’ SEDAR+ and SEC filings, press releases, and risk disclosures.

Forward-Looking Statements

This document contains forward-looking statements within the meaning of applicable securities legislation. Such statements include, without limitation, statements regarding: Planet Ventures’ investment strategy and objectives; anticipated developments in the commercial space industry, including the growth of orbital energy and space robotics markets; the projected growth of the global space economy; Planet Ventures’ expectations regarding the strategic importance of its investments in Mantis Space and General Astronautics; the anticipated role of orbital energy technologies and robotic servicing systems in future in-orbit operations; and the potential for these technologies to become foundational to the next generation of commercial space activity.

Forward-looking statements are not guarantees of future performance. Readers are cautioned not to place undue reliance on forward-looking statements. The forward-looking statements contained in this document are made as of the date hereof and Planet Ventures undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws.

Risk Factors

Investing in Planet Ventures and its portfolio companies involves a high degree of risk. The following is a summary of key risk factors. This is not an exhaustive list, and additional risks may exist that are not currently known:

  • Early-Stage Investment Risk. Portfolio companies have limited operating histories and are pre-revenue. Investments are speculative and may result in a total loss of capital.
  • Technology Risk. The orbital energy and lunar habitation technologies underlying the company’s investments are unproven at commercial scale and may not be successfully developed or deployed.
  • Regulatory Risk. Space sector operations require licenses and approvals from domestic and international regulatory bodies. Failure to obtain or maintain these could materially delay or prevent operations.
  • Market Risk. Commercial demand for in-space power systems and lunar services has not been established at scale. Projected market growth may not be realized within anticipated timeframes.
  • Liquidity Risk. Investments in private, early-stage companies are illiquid. There is no guarantee of a market for these securities or the ability to exit on favorable terms.
  • Capital Risk. Portfolio companies may require additional funding that may not be available, or may be available only on dilutive or restrictive terms.
  • Macroeconomic and Geopolitical Risk. Adverse macroeconomic conditions or geopolitical developments could disrupt the company’s investment strategy or the operations of portfolio companies.
  • Key Personnel Risk. The company’s performance depends in part on retaining key personnel and advisors. Loss of key individuals could adversely affect the company’s operations and investment activities.

The Untapped Potential of Greenland’s Jameson Land Basin Creates Major Opportunity for Greenland Energy Company (NASDAQ: GLND)

  • The Jameson Land Basin in Greenland is emerging as one of the world’s largest remaining underexplored onshore hydrocarbon regions, spanning more than 8,400 square kilometers.
  • By agreeing to fully fund the drilling at the project, Greenland Energy Company will acquire 70% of the project, while the remaining 30% remains with 80 Mile, the current owner of the project.
  • Greenland Energy Company has contracted Halliburton, one of the largest companies in the space, to handle project management and offer support for logistics planning.

There are few opportunities in the global oil and gas sector as compelling as the Jameson Land Basin in Greenland, widely viewed as one of the world’s largest remaining underexplored onshore basins. Spanning more than 8,400 square kilometers (roughly 2 million acres), the basin has been the subject of extensive geological and seismic analysis over several decades, with historical industry estimates suggesting the broader basin system could contain tens of billions of barrels of oil equivalent.

The basin has attracted significant industry attention for decades, with historic exploration and related activity by major energy players representing more than $275 million in today’s dollar, including ARCO. That level of interest reflects the extraordinary scale and potential of the asset.

The asset is currently 100%-owned by 80 Mile, an exploration and development company that recently entered into an agreement with Greenland Energy (NASDAQ: GLND) to advance the project toward drilling.

Under the agreement, two 3,500-meter wells are scheduled to be drilled during the second half of 2026, with all drilling costs to be fully funded by Greenland Energy Company. Upon completion of the program, Greenland Energy Company will earn a 70% interest in the project, while 80 Mile will retain a significant 30% stake.

To support the initiative, Greenland Energy Company has partnered with Halliburton, one of the world’s largest oilfield services providers. The agreement covers integrated consulting services and logistical management, including the coordination, planning, transportation, and handling of equipment, services, and materials required for Arctic operations.

The collaboration with Halliburton, alongside additional agreements with Stampede Drilling, is expected to provide best-in-class drilling capabilities, operational expertise, and advanced technologies for what could become the first onshore exploration well ever drilled in the Jameson Land Basin.

Commenting on the Halliburton agreement, Greenland Energy Company CEO Robert Price stated: “By working with Halliburton, we can tap into world-class expertise and advanced technologies that will enhance drilling accuracy, safety, and efficiency under Arctic conditions. This agreement strengthens our operational platform and emphasizes our commitment to technical excellence and responsible development in a frontier basin.”

For more information, visit the company’s website at www.GreenlandEnergyCo.com.

NOTE TO INVESTORS: The latest news and updates relating to GLND are available in the company’s newsroom at https://ibn.fm/GLND

Forward-Looking Statements

This communication contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995 and within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained herein other than statements of present or historical fact, including, without limitation, statements regarding Greenland Energy Company’s (the “Company”) future financial performance, business strategy, operations, financial position, estimated revenues and losses, projected costs, prospects, plans, objectives of management, and expected benefits of the Company’s recent business combination, are forward-looking statements. Forward-looking statements are generally identified by the use of words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “project,” “forecast,” “potential,” “predict,” or the negative of these terms or similar expressions, although not all forward-looking statements contain such identifying words.

These forward-looking statements are based on management’s current expectations, assumptions and beliefs regarding future events and are based on information currently available to the Company. These statements involve a number of risks and uncertainties, many of which are difficult to predict and are beyond the Company’s control, and actual results may differ materially from those expressed or implied by these forward-looking statements. Factors that could cause actual results to differ materially include, among others: (i) Exploration and Geological Risks, including the Company’s status as a development-stage company with no operating history, revenues, or proved reserves; the inherent uncertainty in prospective resource estimates, including that the 13 billion barrel estimate is based on undiscovered accumulations with no certainty of discovery or commercial viability; geological complexity arising from limited seismic data coverage, pervasive igneous intrusions, faulting patterns, and significant Tertiary uplift creating thermal maturity uncertainty; the fact that the basin has never produced a commercial discovery despite decades of study dating back to the 1970s, and a 2008 USGS report stating less than a 10% chance of containing a technically recoverable hydrocarbon accumulation; and high-cost frontier exploration with estimated well costs of $40 million for the first well and $20 million for subsequent wells; (ii) Operational and Environmental Risks, including the challenges of operating in a remote Arctic location with extreme climate, harsh weather, limited daylight, no existing infrastructure, and seasonal access windows for equipment and personnel; drilling hazards such as blowouts, equipment failures, well control events, environmental releases, and accidents inherent in oil and gas operations; reliance on third-party contractors; and climate change scrutiny, as operations in Greenland face increasing opposition from environmental groups and institutional investors due to Arctic drilling concerns; (iii) Regulatory and Political Risks, including the 2021 Greenland drilling moratorium, and while licenses are grandfathered, future regulatory changes could jeopardize operations; geopolitical tensions, including U.S. interest in acquiring Greenland and Greenland’s internal independence movements that could affect operations; permit requirements, as drilling requires Environmental Impact Assessment approval and Field Activities Application approval from Greenlandic authorities; and forfeiture risk, as failure to meet drilling milestones could result in loss of the Company’s right to earn working interests; (iv) Financial and Capital Risks, including significant capital requirements and the need for substantial funding beyond current resources to complete the drilling program; commodity price volatility, as oil, gas, and NGL prices are highly volatile and will heavily influence project viability; a long development timeline during which market conditions may change significantly before potential production, unlike short-cycle shale projects; going concern uncertainty and substantial doubt about the Company’s ability to continue as a going concern without additional financing; and energy transition risk, as global demand for oil may decline due to electric vehicle adoption, renewable energy policies, and changing consumer preferences; and other risks and uncertainties as set forth in the Company’s Prospectus filed with the Securities and Exchange Commission pursuant to Rule 424(b)(4) under the Securities Act on April 29, 2026, in the section titled “Risk Factors.”

Forward-looking statements speak only as of the date they are made. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Frontieras North America Inc. Targets Trillion-Dollar Energy, Chemicals Markets with Transformative Processing Technology

  • The company’s FASForm(TM) technology produces materials already used across multiple existing segments. 
  • What differentiates Frontieras within these sectors is the breadth of outputs generated from a single feedstock.
  • Frontieras broke ground last month on its first commercial-scale project, which is designed to process approximately 7,500 tons of coal per day.

For decades, coal’s critics and coal’s defenders have been arguing about the same thing: whether to burn it. Frontieras North America Inc. has a different question entirely. What happens when the industry stops burning coal and starts fractionating it?

The answer, according to the company’s FASForm(TM) technology, is six commercial product streams — diesel, naphtha, jet fuel, hydrogen, purified industrial carbon and ammonium sulfate fertilizer — all produced from a single feedstock, through a closed-loop process, with no combustion and no waste. The markets those products serve carry a combined estimated value exceeding $2.1 trillion. That’s what coal actually is, when the world stops asking it to be something it was never designed to be.

Clearly, the scale of the opportunity targeted by Frontieras is significant.      Rather than relying on emerging or speculative demand categories, the company’s product portfolio aligns with markets that already support large-scale global trade, mature supply chains and benchmark commodity pricing structures. These include transportation fuels, hydrogen, petrochemical feedstocks, industrial carbon products and agricultural inputs that are deeply integrated into the global economy.

Crucially, Frontieras does not depend on creating new categories of consumption or introducing entirely new infrastructure systems. Instead, the company’s FASForm process produces materials already used across transportation, aviation, agriculture, steelmaking, refining and industrial manufacturing. Diesel remains one of the world’s main transportation fuels, powering freight movement, construction equipment and industrial machinery. Jet fuel demand continues to rise alongside global aviation activity, while hydrogen plays a critical role in refining, chemical production and industrial processing.

The company’s inclusion of naphtha within its product slate also aligns Frontieras with one of the core feedstocks used in global petrochemical manufacturing. Naphtha is widely used in the production of plastics, synthetic fibers, industrial solvents and chemical intermediates that support countless downstream industries. At the same time, Frontieras’s FASCarbon(TM) product positions the company within technical carbon and coke markets tied to steel manufacturing, industrial heating and materials production.

Agricultural markets further expand the company’s market potential. The ammonia and sulfur compounds generated during the FASForm process can be repurposed into fertilizer products, including ammonium sulfate and sulfuric acid. Fertilizers remain essential to global food production systems, with demand supported by population growth and agricultural intensity worldwide. Industry estimates place the global fertilizers market at roughly $230 billion in 2025, reflecting continued demand tied to agriculture, crop yields and global food production.

What differentiates Frontieras within these sectors is the breadth of outputs generated from a single feedstock. The company’s FASForm process fractionates coal into multiple commercial products simultaneously rather than using coal for a single end purpose. The process produces approximately 2.3 barrels of liquid fuels from each ton of coal processed while also generating hydrogen and purified technical carbon products. This approach allows one facility to participate across several large industrial markets at the same time.

The company’s first commercial-scale project in Mason County, West Virginia, demonstrates the scale at which Frontieras intends to operate. Frontieras recently broke ground on the facility, which is designed to process approximately 7,500 tons of coal per day, or roughly 2.7 million tons annually. According to the company, this volume represents approximately 0.5% of current annual U.S. coal production, a scale designed to remain aligned with existing market demand, transportation infrastructure and logistics systems.

This incremental scaling strategy is an important component of the company’s market positioning. Rather than overwhelming existing commodity markets with oversized production capacity, Frontieras has structured its facility design around integration with established industrial demand profiles. Existing transportation networks, refining systems, industrial buyers and commodity trading structures already support the products the company plans to produce. 

The Mason County facility also reflects the company’s focus on infrastructure compatibility. Frontieras has stated that the plant will use existing coal supply chains while producing fuels, hydrogen and industrial materials. The company has already secured buyers for portions of the output. The company’s long-term feedstock and offtake arrangements reinforce its strategy of operating within established industrial ecosystems rather than building entirely new ones.

Frontieras’ products serve several of the world’s most essential industries. Diesel and jet fuel support transportation, freight and aviation, while hydrogen is widely used in refining and industrial manufacturing. Technical carbon and coke products remain important for steel production and industrial heating, and fertilizer products help support global agriculture and food production. Demand across these sectors continues to grow alongside infrastructure development, manufacturing activity and population growth worldwide.

Coal itself also remains one of the world’s most abundant energy resources. According to the U.S. Energy Information Administration, global proved recoverable coal reserves total approximately 1.16 trillion short tons. Frontieras’ model is built on increasing the economic value extracted from that resource by converting it into multiple industrial outputs rather than limiting it to a single-use fuel source.

As Frontieras North America advances its first commercial deployment, the company is positioning itself at the intersection of established industrial demand and abundant domestic feedstock supply. By aligning its product portfolio with trillion-dollar global markets supported by existing infrastructure, mature supply chains and long-standing industrial applications, Frontieras is building a scalable model centered on coal’s value as a diversified industrial resource rather than a single-purpose commodity.

For more information about Frontieras, visit the company’s website at www.Frontieras.com.

NOTE TO INVESTORS: The latest news and updates relating to Frontieras are available in the company’s newsroom at https://ibn.fm/Frontieras

Regentis Biomaterials Ltd. (NYSE American: RGNT) and the Off-the-Shelf Opportunity in Knee Cartilage Repair

  • Approximately 472,500 arthroscopic knee procedures in the U.S. each year involve cartilage damage, yet no approved off-the-shelf solution capable of regenerating hyaline-like cartilage is currently available in the U.S. market
  • Regentis’ GelrinC(R) is a cell-free hydrogel implant designed to repair focal knee cartilage defects in a single approximately 10-minute procedure, with CE Mark approval in Europe and a pivotal U.S. FDA trial now more than 50% enrolled
  • A newly patented solvent-free manufacturing process that increases GelrinC(R) production yield by 400% signals Regentis’ preparation for commercial scale-up as clinical and regulatory milestones approach

Knee cartilage damage remains one of the most stubborn problems in orthopedic medicine. Unlike many other tissues in the body, articular cartilage has little natural ability to heal because it lacks both direct blood supply and the biological machinery required for meaningful regeneration. For decades, treatment options have reflected that limitation. Microfracture, the long-standing standard of care, attempts to stimulate repair by drilling into the underlying bone in an attempt to mimic a repair trigger. It can provide short-term symptom relief, but long-term cartilage durability remains a recognized challenge with standard treatment. More advanced cell-based therapies exist, but they introduce substantial complexity, cost, manufacturing requirements, and long procedural delays that limit broader adoption. Despite roughly 472,500 arthroscopic knee procedures in the U.S. each year involving knee cartilage damage, the market still lacks an approved, ready-to-use truly regenerative solution capable of combining procedural simplicity with sustained long-term outcomes. Regentis is positioning durability as a central differentiator, with clinical data demonstrating sustained outcomes over extended follow-up periods.

Regentis Biomaterials (NYSE American: RGNT) is targeting that gap with GelrinC(R), its lead regenerative cartilage repair platform designed as a cell-free alternative to conventional treatment pathways.

The Limitations of Today’s Standard

For active patients with focal cartilage damage, current treatment options often involve trade-offs.

Microfracture remains widely used because it is relatively straightforward and familiar to orthopedic surgeons, but the tissue it produces is fibrocartilage rather than true hyaline cartilage, making durability a persistent concern. Cell-based procedures offer a more biologically sophisticated approach, but typically require an initial biopsy, weeks of laboratory cell expansion, and a second surgical procedure for implantation. Costs for those approaches can range from approximately $38,000 to $45,000 per case.

Other repair methods may involve harvesting plugs from healthy bone and cartilage and requiring two surgeries, introducing additional trauma through surgical complexity and donor-site concerns. No currently available cartilage repair solution combines off-the-shelf availability, a single short procedure, regenerative cartilage restoration, and long-term durability in a single treatment approach.

A Different Regenerative Model

GelrinC(R) represents a fundamentally different regenerative approach designed to simplify one of orthopedics’ most complex treatment categories.

The product is an acellular hydrogel composed of polyethylene glycol and denatured fibrinogen, delivered into a cartilage defect in liquid form and then cured into a solid degradable hydrogel implant using ultraviolet light. The implant is designed to gradually resorb in a synchronized manner as native surrounding cells migrate inward, supporting regeneration of hyaline-like cartilage tissue over time.

From a practical standpoint, the workflow is materially simpler than cell-based alternatives. The procedure takes approximately 10 minutes, can be performed using open or minimally invasive techniques, and does not require tissue harvesting, cell culturing, or delayed reimplantation. Surgeons use the product at the point of care rather than coordinating a multi-step treatment pathway.

That combination of procedural simplicity and regenerative intent is central to the company’s commercial thesis.

Clinical Progress and Commercial Preparation

Clinical data have provided the early foundation for that thesis.

In a Phase II study involving 56 patients across Northern Europe and Israel, GelrinC(R) demonstrated statistically significant improvement in its primary endpoint measuring KOOS outcomes at 24 months. GelrinC(R) treatment resulted in 100% greater overall KOOS (Knee Injury and Osteoarthritis Outcome Score) clinical outcomes compared to microfracture controls, including significant improvements in pain, function, and patient recovery measures, compared to microfracture controls.  In parallel, quantitative MOCART imaging scores – a validated, FDA-accepted MRI assessment method – suggested near-complete structural repair and among the highest reported cartilage repair outcomes in the field. No serious adverse events were reported.

Those results supported CE Mark marketing approval in Europe, where Regentis is now actively building a commercialization infrastructure and physician adoption pathways ahead of planned market entry. 

In April, the company announced a collaboration with Humanitas Research Hospital in Milan, one of Europe’s leading orthopedic and sports medicine centers, alongside internationally recognized cartilage regeneration expert Prof. Elizaveta Kon. The initiative is part of Regentis’ broader strategy to establish a European Centers of Excellence network designed to support surgeon education, clinical guidance, and large-scale physician adoption ahead of commercialization.

Commercial readiness is also showing up operationally. In March, Regentis announced a newly developed solvent-free manufacturing process that more than quadruples GelrinC(R) production yield per batch. Beyond improving production economics, the manufacturing advancement suggests active preparation for broader commercial deployment.

The U.S. Regulatory Path

In the United States, GelrinC(R) is advancing through a pivotal FDA study under an Investigational Device Exemption pathway.

The study uses a single-arm design with historical microfracture controls previously accepted by regulators, rather than a concurrent randomized comparator arm. Enrollment is targeted at 80 patients, with more than half already recruited and treated according to company disclosures.

If enrollment proceeds as expected, the program could move toward PMA submission in late 2027.

Orthopedic innovation often moves slowly, particularly in categories where legacy procedures remain entrenched despite well-understood limitations. Knee cartilage repair appears to be one of those markets. Regentis is pursuing an opportunity built around procedural simplicity, regenerative intent, and commercial practicality in a category where those elements have rarely aligned in a single product.

For more information, visit the company’s website at www.Regentis.co.il.

NOTE TO INVESTORS: The latest news and updates relating to RGNT are available in the company’s newsroom at https://ibn.fm/RGNT

From Our Blog

Frontieras North America Inc. Reimagines Coal for the AI Economy

June 1, 2026

Artificial intelligence (“AI”) is transforming the way the world uses energy. From massive data centers to advanced manufacturing systems, the technologies powering the AI boom require enormous amounts of reliable electricity, putting growing pressure on existing energy infrastructure. Frontieras North America is positioning itself within that shift through its proprietary FASForm(TM) platform, which converts coal […]

Rotate your device 90° to view site.